T. Leal

发表

Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.

J. Eickhoff, A. Tevaarwerk, R. Love, 2010, Clinical Breast Cancer.

Clinical Use of the Low-Molecular-Weight Heparins in Cancer Patients: Focus on the Improved Patient Outcomes

H. Robins, B. Chao, T. Leal, 2011, Thrombosis.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

A. Tafreshi, J. Riess, M. Pietanza, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay

W. Burlingham, E. Jankowska-Gan, T. Leal, 2020, Journal for immunotherapy of cancer.

Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.

P. Yadav, A. Baschnagel, J. Witt, 2020, Clinical lung cancer.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound

S. Reeder, T. Campbell, D. Tamada, 2022, Frontiers in Rehabilitation Sciences.

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

R. Neuwirth, K. Venkatakrishnan, C. Takimoto, 2011, Cancer Chemotherapy and Pharmacology.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

H. Wakelee, J. Nieva, T. Shaffer, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?

T. Kruser, T. Leal, Eric G. Nesbit, 2019, Translational lung cancer research.

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

N. Reinmuth, Ying Cheng, A. Mansfield, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

N. Reinmuth, Ying Cheng, A. Mansfield, 2019, Annals of Oncology.

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, M. Socinski, V. Velcheti, 2022, Nature Medicine.

Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

M. Mehta, H. Robins, Julie E. Chang, 2011, Current cancer therapy reviews.

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

C. Blakely, D. Waterhouse, E. Garon, 2021, Annals of Oncology.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

S. Ramalingam, T. Leal, 2022, Cell reports. Medicine.

Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer

D. Beebe, J. Lang, S. Berry, 2022, Biomarker research.

Implementing value assessment in oncology practice: A single-center experience

T. Leal, Mary S Mably, Jason J Bergsbaken, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).

Xiaohong Yan, S. Neuteboom, D. Waterhouse, 2020 .

Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities

T. Leal, Jason J Bergsbaken, Catherine E Renna, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting

A. Mansfield, T. Mekhail, F. Braiteh, 2019, Journal of Thoracic Oncology.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

S. Ou, J. Christensen, Melissa L. Johnson, 2020, European Journal of Cancer.

Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report

H. Robins, T. Leal, 2009, Cancer Chemotherapy and Pharmacology.

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

S. Ramalingam, D. King, M. Razaq, 2020 .

Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

Steven E. Schild, Renato Martins, Billy W. Loo, 2017 .

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Renato Martins, Thomas J Dilling, Steven E Schild, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

P. Jänne, S. Ou, J. Christensen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non–Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts

A. Baschnagel, R. Kimple, Shuang G Zhao, 2021, Molecular Cancer Therapeutics.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

C. Paweletz, J. Christensen, S. Ou, 2022, The New England journal of medicine.

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

K. Wisinski, R. O'Regan, J. Malhotra, 2022, Cancer medicine.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Renato Martins, Joe Y. Chang, Thomas J Dilling, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Keunchil Park, T. Hsia, O. Molinier, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health Literacy and Health-Related Quality of Life Among a Population-Based Sample of Cancer Patients

M. Palta, M. Walsh, A. Trentham-Dietz, 2015, Journal of health communication.

Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board.

Ruth Warren, Mark E. Burkard, Joshua M. Lang, 2017, JCO precision oncology.

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

N. Hanna, S. Perkins, S. Althouse, 2021 .

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy.

J. Christensen, C. Blakely, P. Olson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2022, Annals of Oncology.

OA03.08 Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI): Topic: Medical Oncology

H. Wakelee, C. Liang, L. Gandhi, 2017 .

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

M. Socinski, V. Velcheti, D. Shames, 2019, Annals of Oncology.

Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.

N. Hanna, S. Jabbour, J. Naidoo, 2020 .

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

A. Argento, R. C. McDonald, J. Grigorieva, 2020, Current medical research and opinion.

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).

M. Socinski, V. Velcheti, D. Fabrizio, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib

J. Neal, H. Wakelee, C. Liang, 2019, Journal of Thoracic Oncology.

43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

D. Waterhouse, E. Garon, A. Spira, 2022, Annals of Oncology.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.

N. Hanna, A. Ganti, S. Jabbour, 2019, Journal of Clinical Oncology.

High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1

D. Beebe, J. Lang, S. Berry, 2016, PloS one.

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

D. Cella, T. Owonikoko, S. Ramalingam, 2020, Cancer medicine.

Exclusive Liquid Repellency: An Open Multi-Liquid-Phase Technology for Rare Cell Culture and Single-Cell Processing.

D. Beebe, J. Lang, S. Berry, 2018, ACS applied materials & interfaces.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Immunotherapy in previously treated non-small cell lung cancer (NSCLC).

S. Ramalingam, T. Leal, 2018, Journal of Thoracic Disease.